Archimedes
Natasha Lockwood, MBA, is an accomplished professional with extensive experience in patient operations and call center management. Currently serving as the Director of Call Center Operations at Archimedes, Natasha has previously held leadership positions including VP of Patient Operations and Senior Director of Patient Operations at Everly Health, as well as Sr Director of Patient Operations at PWNHealth. Additional roles include Director of Contact Center Operations at Solera Health and Contact Center Operations Manager at Matrix Medical Network. Natasha Lockwood earned a Master of Business Administration in Business Administration and Corporate Social Responsibility from Southern New Hampshire University and a Bachelor of Business Administration in Business Administration and Management from the University of Florida.
This person is not in any offices
Archimedes
Specialty drug spend is the single fastest growing healthcare expense. Recognizing the potential clinical value of these drugs, plan sponsors want to provide them to their enrollees—but to maintain an affordable, sustainable benefit in this rapidly changing environment, they must also control costs. To do this, plan sponsors need quantitative information about which strategies work to target drugs to those in need of them and they must minimize use of clinically ineffective therapies and reduce waste. However, the guidance and services provided to plan sponsors to achieve these goals is not always objective or complete. Recognizing these challenges, Archimedes offers specialty drug management solutions for health plans, TPAs, employers, labor groups, and other plan sponsors across the U.S, without any potential conflicted financial relationships with specialty pharmacies or PBMs. Like the scientist and inventor who provided the inspiration for our name, we leverage an unmatched combination of analytic expertise, technological capabilities, experience, and pragmatism to provide plan sponsors with the support that they really need to control the growing cost of specialty drugs across the pharmacy and medical benefits. Fundamental to our business is the belief that full visibility into the economics and clinical performance of a specialty drug program is critical to making informed decisions concerning specialty drug management.